Lexaria Bioscience (LEXX) risk factors, FY2024 10-K

Other

1. 01DehydraTECH-enabled pharmaceutical products may not successfully proceed to commercialization
2. 02If we are unable to retain and hire qualified personnel, we may not be able to implement our business plan successfully
3. 03We face substantial competition, which may result in others discovering, developing and/or commercializing technology or products similar to ours before or more successfully than us
4. 04Any failure in protecting our intellectual property may have a negative impact adverse effect on our ability to develop and license DehydraTECH
5. 05Technological R&D in the bioscience industry involves a lengthy, expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete our studies or trials
6. 06regulators may require the submission of additional data or impose other requirements before granting permission to proceed
7. 07If we are unable to obtain and maintain sufficient patent protection, or if the scope of the patent protection is not sufficiently broad, our competitors could develop technology similar to ours
8. 08We are dependent on the services of third parties and unsatisfactory performance will negatively affect our Company
9. 09Any failure to prevent or mitigate security breaches and improper access to or disclosure of our data or our user data could result in the loss or misuse of such data, which could harm our business and reputation and diminish our competitive position
10. 10We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets
11. 11Without additional financing to develop our business plan, our business may fail
12. 12The longer-term growth of our business depends on our ability to expand our portfolio of patents and industry segments where DehydraTECH is demonstrably applicable, which may require substantial financial resources and may ultimately be unsuccessful
13. 13We may enter into collaborations with third parties for the development and commercialization of our product candidates. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates
14. 14view product candidates discovered in collaboration as competitive with their existing product candidates or products. They may cease to devote resources to the development of collaborative product candidates
15. 15Our product candidates are in an early stage of development and may fail or experience significant delays or may never advance to the clinical stage, which may materially and adversely impact our business
16. 16Pharmaceutical products incorporating DehydraTECH have never been approved for the treatment of disease
17. 17Any success achieved at a given stage of the clinical trials does not guarantee that the future achievement of success at any subsequent stage, including without limitation, final FDA approval
18. 18Pharmaceutical products using DehydraTECH with CBD as an API have never been approved for the treatment of any disease
19. 19Regulation of non-pharmaceutical hemp-based CBD products is evolving
20. 20Controlled substance legislation differs between localities. Legislation in certain jurisdictions may restrict or limit our ability to develop and commercialize products using DehydraTECH
21. 21The trading price of the shares of our common stock could be highly volatile and as such investors could incur substantial losses
22. 22Our by-laws do not contain anti-takeover provisions, which could result in a change of our executive management and directors if there is a take-over of our Company
23. 23We do not intend to pay any dividends on our shares
24. 24Purchasers of our shares may incur dilution
25. 25We are a “smaller reporting company” under the SEC’s disclosure rules and have elected to comply with the reduced disclosure requirements applicable to smaller reporting companies